International application No. PCT/JP2004/014207

A.	CLASSIF	ICATION	OF	SUBJECT	MATTER

Int.Cl7 C12N15/09, A61K45/00, A61P1/16, A61P11/06, A61P31/12, A61P31/14, A61P35/00, A61P37/04, A61P37/06, A61P37/08, C07K14/705, C07K16/28,C12N1/15, C12N1/19, C12N1/21, C12N5/00,

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl7 C12N15/09, A61K45/00, C07K14/705, C07K16/28, C12N1/15, C12N1/19, C12N1/21, C12N5/00, C12P21/02, C12Q1/02, G01N33/15, G01N33/50

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CA/MEDLINE/BIOSIS/EMBASE/BIOTECHABS/WPIDS(STN), GenBank/EMBL/DDBJ/GeneSeq, SwissProt/PIR/GeneSeq

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
x	EP 1201681 A (Millennium Pharmaceuticals, Inc.), 02 May, 2002 (02.05.02), Full text; Seq. ID. Nos. 6, 34 & US 2003175890 A	1-10,14,19,
P,X	WO 03/89624 A (UAB RESEARCH FOUNDATION), 30 October, 2003 (30.10.03), Full text; Seq. ID. Nos. 27, 28 (Family: none)	1-7,19,20

	Further do	ocuments are listed in the continuation of Box C.		See patent family annex.	
* "A" "E"	document d	gories of cited documents: efining the general state of the art which is not considered icular relevance	"T"	later document published after the inte date and not in conflict with the applica the principle or theory underlying the in	ation but cited to understand
"L"	filing date L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) O" document referring to an oral disclosure, use, exhibition or other means		"X"	document of particular relevance; the c considered novel or cannot be considered when the document is taken alone	larmed invention cannot be lered to involve an inventive
"O" "P"			"Y"	considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
		ober, 2004 (15.10.04)	Date	of mailing of the international searce 02 November, 2004 (
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer			
Facsimile No.		Telephone No.			
Form F	CT/ISA/21	0 (second sheet) (January 2004)			

International application No.

PCT/JP2004/014207

В	ox No.	I	Nucleotide and/or amino acid sequence(s) (Continuation of item1.b of the first sheet)
1.	With	n regar	d to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed the international search was carried out on the basis of:
	a.	type (of material a sequence listing table(s) related to the sequence listing
	b.	form	in written format in computer readable form
	c.		of filing/furnishing contained in the international application as filed filed together with the international application in computer readable form furnished subsequently to this Authority for the purposes of search
2.		or fur	dition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed mished, the required statements that the information in the subsequent or additional copies is identical to that in the cation as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.	Addi		comments:
			•
	-		

International application No.

PCT/JP2004/014207

Box No. II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
1. Claims	search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: Nos.: they relate to subject matter not required to be searched by this Authority, namely:
because extent the Concern 11 to 13 by the de 6 and dis	Nos.: 11-13, 15-18 they relate to parts of the international application that do not comply with the prescribed requirements to such an hat no meaningful international search can be carried out, specifically: ling the ligand, the agonist and the antagonist according to claims and 15 to 18, it is impossible to find anything that is supported escription in the meaning within Patent Corporation Treaty Article sclosed in the description in (continued to extra sheet) Nos.: they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box No. III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
Aprotein by SEQ ID amino acid in common protein. the prior Japanese cell recedefined in Therefool. As all reclaims. 2. X As all seany additionally as any additionally as any additionally search as any additionally search as any additionally search as any additionally search and a search an	Rearching Authority found multiple inventions in this international application, as follows: In as set forth in claim 1 comprising an amino acid sequence represented of NO:2 or 4 and the protein as set forth in claim 1 comprising the disequence represented by SEQ ID NO:6 have no novel chemical structure but are common to each other exclusively in being an NK cell receptor. However, NK cell receptor proteins had been publicly known before ity date of the present case as reported in No.2003-527105 Published translation of PCT international publication. Thus, being an NK aptor protein cannot be considered as a special technical matter as in Patent Cooperation Treaty Rule 13.3. Te, it does not appear that there (continued to extra sheet) equired additional search fees were timely paid by the applicant, this international search report covers all searchable archable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of tional fee. Some of the required additional search fees were timely paid by the applicant, this international search report covers see claims for which fees were paid, specifically claims Nos.:
	ired additional search fees were timely paid by the applicant. Consequently, this international search report is d to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Proto	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

International application No.

PCT/JP2004/014207

Continuation of A. CLASSIFICATION OF SUBJECT MATTER (International Patent Classification (IPC))

Int.Cl7 C21P21/02, C12Q1/02, G01N33/15, G01N33/50

(According to International Patent Classification (IPC) or to both national classification and IPC)

Continuation of Box No.II-2 of continuation of first sheet(2) the meaning within Patent Corporation Treaty Article 5.

Continuation of Box No.III of continuation of first sheet(2)

is a technical relationship between the inventions of the parts relating to a protein as set forth in claim 1 comprising an amino acid sequence represented by SEQ ID NO:2 or 4 and the inventions of the parts relating to the protein as set forth in claim 1 comprising the amino acid sequence represented by SEQ ID NO:6, among the inventions as set forth in claims 1 to 20, involving one or more of the same or corresponding special technical features. Thus, these groups of inventions are not considered as being so linked as to form a single general inventive concept.

Such being the case, the present international application does not comply with the requirement of unity of invention.